Venture Capital

Destination marketing leader Digital Edge is now Go Fish Tourism + Business Events, integrating AI and expanded services to unify leisure and business travel promotion.

After a mixed earnings report, ScanSource's CFO will outline the firm's pivot to recurring revenue and converging tech at a key investor conference.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

A new Dubai-based VC firm is launching with a radical model: providing startups with a 24/7 AI workforce to slash costs and accelerate growth.

Rise Wellness launches its new 30g carbonated protein drink at Costco, betting on fizz and function to capture a rapidly growing, competitive market.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

With an $11.75M boost, a new device promises blood results in minutes, not hours, signaling a major pharma player's strategic pivot into diagnostics.

With sales rising and key FDA milestones met, Australian biotech Immuron resets its strategy, seeking partners to fund its promising infectious disease pipeline.

A new partnership between Salience Labs and Tower Semiconductor aims to mass-produce optical switches, a critical technology for faster, greener AI data centers.

As global ESG rules become a complex web, Datamaran's new AI platform aims to help firms move from reactive compliance to proactive corporate strategy.

With a new CEO at the helm and a pivotal trial for its lead drug on the horizon, all eyes are on PureTech's upcoming investor conference presentation.

The diabetes tech firm secures major funding for innovation and acquisitions, using a savvy financial strategy to protect current shareholder value.

A new tech startup is launching an AI platform to replace high-pressure sales with transparent pricing, promising to cut homeowners' roof costs by up to 50%.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

Navitas Semiconductor accepts short-term losses for a future in AI data centers and energy, signaling a major shift in the power electronics landscape.

Following strong Q4 earnings, Datadog will detail its AI and cloud strategy at a major conference, with investors and tech leaders watching closely.

After a major trial miss sent its stock tumbling, GRAIL will face investors to pitch its vision for the future of early cancer detection technology.